Tiagabine Hydrochloride Patent Expiration

Tiagabine Hydrochloride was first introduced by Cephalon Inc in its drug Gabitril on Sep 30, 1997. 5 different companies have introduced drugs containing Tiagabine Hydrochloride.


Tiagabine Hydrochloride Patents

Given below is the list of patents protecting Tiagabine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Gabitril US5958951 Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride Jun 10, 2017

(Expired)

Cephalon
Gabitril US5866590 Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation Apr 29, 2016

(Expired)

Cephalon



Tiagabine Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Tiagabine Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Tiagabine Hydrochloride. The first generic version for Tiagabine Hydrochloride was by Sun Pharmaceutical Industries Ltd and was approved on Nov 4, 2011. And the latest generic version is by Msn Laboratories Private Ltd and was approved on Nov 16, 2021.

Given below is the list of companies who have filed for Tiagabine Hydrochloride generic, along with the locations of their manufacturing plants worldwide.